Zytomegalievirus-Infektion der Maus unter Cytosin-Arabinosid-Behandlung

Cytomegalovirus infections in mice treated with cytosine arabinoside

Zusammenfassung

Cytosin-Arabinosid (ARA-C) wurde im Tierversuch auf seine antivirale Aktivität gegen das Mäusezytomegalie-Virus in verschieden hohen Dosen überprüft. Die Substanz wies keine virostatische Wirkung auf, sondern begünstigte im Gegenteil die Virusinfektion. Die Viruskonzentration in der Leber war bei Verabreichung von fünfmal 30 mg/kg Cytosin-Arabinosid etwa 35mal und bei fünfmal 45 mg/kg 70mal größer als bei den nicht behandelten Tieren. Auch die Mortalität war bei den mit Cytosin-Arabinosid behandelten infizierten Tieren dosisabhängig signifikant höher. Cytosin-Arabinosid wirkt beim Menschen ebenfalls immunsuppressiv. Ein ungünstiger Einfluß ist aus diesem Grund bei einer Zytomegalie-Infektion nicht auszuschließen. Daher scheint es bedenklich, Cytosin-Arabinosid therapeutisch einzusetzen.

Summary

The antiviral activity of cytosine arabinoside (ARA-C) against the mouse cytomegalovirus was investigated in animal experiments using various dosages. The substance did not exhibit any virostatic effect, but on the contrary fostered the viral infection. The virus concentration in the liver after administration of five dosages of 30 mg/kg of cytosine arabinoside was 35 times higher than that in untreated animals, and after five dosages of 45 mg/kg was 70 times higher. In addition the mortality rate for infected animals treated with cytosine arabinoside was significantly higher in relation to dosage. Cytosine arabinoside also acts as an immunosuppressor in humans. Adverse effects in cytomegalo-infection can therefore not be excluded. The use of cytosine arabinoside in therapy would thus appear to be highly questionable.

This is a preview of subscription content, access via your institution.

Literatur

  1. 1.

    Brodsky, I., Rowe, W. P. Chronic subclinical infection with mouse salivary gland virus. Proc. Soc. Exp. Biol. 99 (1958) 654.

    Google Scholar 

  2. 2.

    Buthala, D. A. Cell culture studies on antiviral agents: I. Action of cytosine arabinoside and some comparison with 5-iodo-2-deoxyuridine. Proc. Soc. Exp. Biol. 115 (1964) 69.

    Google Scholar 

  3. 3.

    Chonchie, A. F., Barton, B. W., Tobin, J. O. H. Congenital cytomegalovirus infection treated with idoxyuridine. Brit. med. J. IV (1968) 162.

    Google Scholar 

  4. 4.

    McCracken, G. H., Luby, J. P. Cytosine arabinoside in the treatment of congenital cytomegalic inclusion disease. J. Pediat. 80 (1972) 488.

    Google Scholar 

  5. 5.

    Dennis, D. T., Doberstyn, E. B., Awoke, S., Royer, G. L., Renis, H. E. Failure of cytosine arabinoside in treatment of smallpox. Lancet II (1974) 377.

    Google Scholar 

  6. 6.

    Emödi G., Sartorius, J., Just, M., Rohner, F., Bühler, U. Virus studies in the treatment of congenital cytomegalovirus infections by cytosine arabinoside. Helv. Paediatr. Acta 27 (1972) 557.

    Google Scholar 

  7. 7.

    Feigin, R. D., Shackelford, P. G., Vivo, D. C., Haymond, M. W. Floxuridine treatment of congenital cytomegalic inclusion disease. Pediatrics 48 (1971) 318.

    Google Scholar 

  8. 8.

    Goldenberg, D. M., Biro, V., Elster, K., Schricker, K., Sögtrop, H. Laboratory studies on the pharmacology, toxicology and antitumor action of cytosine arabinoside. Arzneim. Forsch. 19. Beiheft (1968) 31.

    Google Scholar 

  9. 9.

    Henson, D., Smith, R. D., Gehrke, J. Murine cytomegalovirus: Observations on growth in vitro, cytopathic effect and inhibition with 5-iododeoxyuridine. Arch. ges. Virusforsch. 18 (1966) 433.

    Google Scholar 

  10. 10.

    Kraybill, E. N., Sever, J. L., Avery, G. B., Movassaghi, N. Experimental use of cytosine arabinoside in congenital cytomegalovirus infection. J. Pediatr. 80 (1972) 485.

    Google Scholar 

  11. 11.

    Osborn, J. E., Medearis, D. N. Studies of the relationship between mouse cytomegalovirus and interferon. Proc. Soc. Exp. Biol. 121 (1966) 121.

    Google Scholar 

  12. 12.

    Peller, P., Goetz, O. Immunsuppression und Cytomegalievirusinfektion. Tierexperimentelle Untersuchungen mit Cyclophosphamid. Res. Exp. Med. 162 (1974) 267.

    Google Scholar 

  13. 13.

    Plotkin, S. E., Stettler, H.: Treatment of congenital cytomegalic inclusion disease with antiviral agents. Antimicrob. Agents Chemother (1969) 372.

  14. 14.

    Rapp, F. Inhibition by metabolic analogues of plaque formation by herpes zoster and herpes simplex viruses. J. Immunol. 93 (1964) 643.

    Google Scholar 

  15. 15.

    Sideropoulos, P., Vasella, F., Schneider, H. J., Ferrazzini, F. Zur Therapie der angeborenen Zytomegalievirusinfektion. Helv. Paediatr. Acta 26 (1971) 258.

    Google Scholar 

  16. 16.

    Stevens, D. A., Jordan, G. W., Waddell, Th. F., Merigan, Th. C. Adverse effect of cytosine arabinoside on disseminated zoster in a controlled trial. N. Engl. J. Med. 289 (1973) 873.

    Google Scholar 

  17. 17.

    Váci, L., Gönczöl, E. The effet of cytosine arabinoside on the multiplication of cytomegalovirus and on the formation of virus-induced intracellular antigens. Acta Virol. 17 (1973) 189.

    Google Scholar 

Download references

Author information

Affiliations

Authors

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Pelle, P., Goetz, O. & Rath, M. Zytomegalievirus-Infektion der Maus unter Cytosin-Arabinosid-Behandlung. Infection 4, 130–133 (1976). https://doi.org/10.1007/BF01638938

Download citation